Residency · Residency · Ophthalmology

Medical Therapy for Glaucoma: Pharmacology and Adherence

Principles of Medical Therapy

IOP reduction is the only treatment proven to slow glaucoma progression, and all current medical therapies work by either decreasing aqueous production or increasing aqueous outflow. The target IOP is individualized for each patient based on the severity of existing damage, baseline IOP, rate of progression, and life expectancy. Monotherapy is preferred as the initial approach, with additional agents added in a stepwise fashion only if the target IOP is not achieved. When selecting medications, the clinician must balance efficacy, side effect profile, dosing frequency, cost, and patient tolerance.

Prostaglandin Analogs (PGAs)

Mechanism

Prostaglandin analogs lower IOP primarily by increasing uveoscleral (non-conventional) outflow. They achieve this by remodeling the extracellular matrix within the ciliary muscle, widening the intercellular spaces and facilitating aqueous drainage through this pathway. Newer agents in this class may also increase trabecular outflow.

Agents

Latanoprost 0.005% (Xalatan) was the first prostaglandin analog and is dosed once daily in the evening, producing approximately 25 to 35% IOP reduction. Bimatoprost 0.01 to 0.03% (Lumigan) is a prostamide dosed once daily with similar efficacy. Travoprost 0.004% (Travatan Z) is dosed once daily and is available in a BAK-free formulation. Tafluprost 0.0015% (Zioptan) is a preservative-free PGA dosed once daily.

Advantages

Prostaglandin analogs provide the most effective single-agent IOP reduction of any drug class, at approximately 25 to 35% from baseline. Their once-daily dosing promotes the best adherence of any glaucoma medication. Systemic side effects are minimal because the drugs act locally. For these reasons, PGAs are the first-line therapy for most patients with POAG and ocular hypertension.

Side Effects

Conjunctival hyperemia is the most common side effect, though it usually diminishes over time. Iris pigmentation darkening is an irreversible change caused by increased melanogenesis, most noticeable in irides with mixed coloration. Prostaglandin-associated periorbitopathy (PAPA) encompasses periorbital skin hyperpigmentation and orbital fat atrophy, which can produce a deepened upper lid sulcus and a sunken appearance. Eyelash hypertrichosis results in longer, thicker, and darker lashes. Cystoid macular edema is a rare but important complication, occurring more frequently in aphakic or pseudophakic eyes and in the postoperative setting. Reactivation of herpes simplex keratitis has been reported, though the association remains controversial; caution is warranted in patients with a history of HSV. Anterior uveitis occurs rarely.

Newer PGA: Latanoprostene Bunod (Vyzulta)

Latanoprostene bunod is a nitric oxide-donating prostaglandin analog that metabolizes to latanoprost acid and nitric oxide. This dual mechanism allows the PGA component to increase uveoscleral outflow while the nitric oxide relaxes the trabecular meshwork and Schlemm canal, increasing conventional outflow as well. The result is slightly greater IOP lowering than latanoprost alone, by approximately 1 to 1.5 mmHg. It is dosed once daily.

Omidenepag Isopropyl (Omlonti)

Omidenepag isopropyl is a non-prostaglandin EP2 receptor agonist that lowers IOP through a different receptor target than traditional PGAs. Importantly, it does not cause periorbital fat atrophy or eyelash changes, making it an attractive option for patients with cosmetic concerns. Dosed once daily, it provides IOP lowering similar to latanoprost.

Glaucoma Medications Summary

Beta-Adrenergic Antagonists (Beta-Blockers)

Mechanism

Topical beta-blockers reduce aqueous humor production by blocking beta-2 adrenergic receptors on the ciliary epithelium. They have no effect on aqueous outflow.

Agents

Timolol 0.25 to 0.5% (Timoptic) is a non-selective beta-blocker dosed twice daily (or once daily in its gel-forming formulation). Betaxolol 0.25 to 0.5% (Betoptic) is a selective beta-1 blocker, offering less bronchospasm risk but slightly less IOP-lowering efficacy. Levobunolol 0.25 to 0.5% is a non-selective agent dosed once or twice daily. Carteolol 1% is non-selective but possesses intrinsic sympathomimetic activity, which may produce less bradycardia.

IOP Reduction

Beta-blockers reduce IOP by approximately 20 to 25% from baseline. They are less effective at night because aqueous production is already reduced during sleep, making the target of their mechanism less active.

Systemic Side Effects (Critical)

The systemic side effects of topical beta-blockers are clinically critical and must be screened for before prescribing. Beta-1 blockade can cause bradycardia, heart block, and hypotension. Beta-2 blockade can trigger bronchospasm, making these agents contraindicated in patients with asthma and severe COPD -- even topical administration can cause fatal bronchospasm. Other systemic effects include masking of hypoglycemia symptoms in diabetic patients, depression, fatigue, decreased libido, exercise intolerance, and exacerbation of myasthenia gravis.

Ocular Side Effects

Ocular side effects are generally mild and include stinging and superficial punctate keratopathy. Decreased corneal sensitivity may also occur.

Important Considerations

Punctal occlusion or eyelid closure for two to five minutes after drop instillation reduces systemic absorption by 50 to 70% -- this technique should be taught to all patients using topical beta-blockers. Resting heart rate and blood pressure should be checked before prescribing, and the clinician must ask about asthma, COPD, and cardiac conditions.

Alpha-Adrenergic Agonists

Mechanism

Alpha-2 adrenergic agonists work through a dual mechanism: they reduce aqueous production and increase uveoscleral outflow. Alpha-1 effects (vasoconstriction, pupil dilation, lid retraction) are less desirable and are minimized with selective alpha-2 agents.

Agents

Brimonidine 0.1 to 0.2% (Alphagan P) is a selective alpha-2 agonist dosed two to three times daily, producing approximately 20 to 25% IOP reduction. A low-dose brimonidine 0.025% formulation (Lumify) is marketed over-the-counter for redness reduction and is not intended for glaucoma treatment. Apraclonidine 0.5 to 1% (Iopidine) is a mixed alpha-1 and alpha-2 agonist used primarily for short-term prevention of IOP spikes after laser procedures. It has high rates of tachyphylaxis and allergic reaction, making it unsuitable for chronic use.

Side Effects

Allergic conjunctivitis is the most significant side effect of brimonidine, occurring in 12 to 15% of patients, typically with onset weeks to months after starting treatment. It manifests as a follicular reaction in the inferior fornix with periocular contact dermatitis. Systemic effects include fatigue, drowsiness, and dry mouth. Brimonidine is strictly contraindicated in children under two years of age because it crosses the blood-brain barrier and can cause life-threatening CNS depression, apnea, hypotension, and hypothermia.

Neuroprotective Properties

Brimonidine may possess neuroprotective properties independent of its IOP-lowering effect. The Low-Pressure Glaucoma Treatment Study suggested less visual field progression with brimonidine compared with timolol at similar IOP levels, though the clinical significance of this potential neuroprotection remains debated.

Carbonic Anhydrase Inhibitors (CAIs)

Mechanism

Carbonic anhydrase inhibitors work by inhibiting carbonic anhydrase II in the ciliary epithelium, reducing bicarbonate and sodium transport and thereby decreasing aqueous production by approximately 40 to 60%.

Topical Agents

Dorzolamide 2% (Trusopt) is dosed three times daily and provides approximately 15 to 20% IOP reduction. Brinzolamide 1% (Azopt) has similar efficacy but is better tolerated because its neutral pH causes less stinging upon instillation.

Systemic Agents

Acetazolamide (Diamox) is the most commonly used oral CAI, dosed at 250 mg four times daily or 500 mg sustained-release twice daily. It is also available intravenously for acute IOP elevation. Methazolamide (Neptazane) at 25 to 50 mg two to three times daily produces fewer renal side effects than acetazolamide.

Topical Side Effects

Topical CAIs can cause stinging, a bitter taste (from drainage through the nasolacrimal duct), and superficial punctate keratopathy. A critical consideration is that topical CAIs can cause irreversible corneal decompensation in eyes with low endothelial cell counts -- they should be avoided in patients with Fuchs dystrophy or other endothelial compromise.

Systemic Side Effects (Oral CAIs)

Oral CAIs produce a distinctive side effect profile. Paresthesias (tingling of the extremities) are the most common complaint. Other effects include metallic taste, gastrointestinal upset, anorexia, and weight loss. Metabolic acidosis (non-anion gap, hyperchloremic) and hypokalemia can develop. Renal calculi form because urinary alkalinization promotes calcium phosphate stone precipitation. Aplastic anemia is rare but potentially fatal and occurs idiosyncratically. Stevens-Johnson syndrome can occur as a sulfonamide allergy reaction -- a sulfa allergy history should be elicited, though the actual cross-reactivity risk is low. Oral CAIs are contraindicated in sickle cell disease because the resulting metabolic acidosis can precipitate a sickling crisis.

Rho-Kinase Inhibitors (ROCK Inhibitors)

Mechanism

Rho-kinase inhibitors target Rho-associated protein kinase in the trabecular meshwork and Schlemm canal endothelium. By relaxing these tissues, they increase trabecular (conventional) outflow -- a unique mechanism among glaucoma drugs that directly addresses the primary site of pathology in POAG. They also reduce episcleral venous pressure, a property not shared by any other glaucoma medication class, and may reduce fibrosis and scar formation.

Agents

Netarsudil 0.02% (Rhopressa) is dosed once daily in the evening and provides approximately 16 to 20% IOP reduction. The fixed combination of netarsudil with latanoprost (Rocklatan) is dosed once daily and represents the most potent single-bottle IOP-lowering agent available, achieving approximately 30 to 36% IOP reduction.

Side Effects

Conjunctival hyperemia is the most common side effect and tends to be more pronounced than with prostaglandin analogs. Cornea verticillata -- whorl-like deposits in the corneal epithelium resembling the vortex keratopathy pattern seen in Fabry disease -- is characteristic of this drug class and reverses upon discontinuation. Petechial subconjunctival hemorrhages and periorbital skin erythema can also occur.

Cholinergic Agents (Miotics)

Mechanism

Direct parasympathomimetics such as pilocarpine stimulate the ciliary muscle to contract, which exerts traction on the scleral spur and opens the trabecular meshwork, increasing conventional outflow. The concomitant pupillary constriction (miosis) also pulls the iris root away from the trabecular meshwork, which is helpful in angle closure. Indirect parasympathomimetics such as echothiophate are irreversible cholinesterase inhibitors that produce more sustained cholinergic stimulation.

Agents

Pilocarpine 1 to 4% is dosed four times daily and reduces IOP by approximately 20 to 25%. A lower-concentration pilocarpine 1.25% (Vuity) is approved specifically for presbyopia. Echothiophate 0.125% (Phospholine Iodide) is used primarily in pediatric accommodative esotropia.

Side Effects

Miosis causes dim vision, decreased night vision, and headache from ciliary spasm. A myopic shift results from sustained ciliary contraction. Miotics increase the risk of retinal detachment through anterior vitreous traction from ciliary body contraction and can promote cataract formation with long-term use. Echothiophate requires special consideration before general anesthesia because it prolongs the action of succinylcholine and must be discontinued preoperatively.

Current Role

Miotics have been largely replaced by newer agents for routine glaucoma management but retain specific indications: acute angle-closure crisis (once IOP has been lowered below approximately 40 mmHg), plateau iris (to maintain peripheral iris tautness), and pigment dispersion syndrome (to reduce lens-iris contact and pigment liberation).

Fixed Combinations

Fixed-combination medications reduce the number of bottles a patient must use and improve adherence. Commonly used combinations include timolol/dorzolamide (Cosopt, dosed twice daily), timolol/brimonidine (Combigan, twice daily), timolol/latanoprost (Xalacom, once daily, not available in the US), netarsudil/latanoprost (Rocklatan, once daily), and brimonidine/brinzolamide (Simbrinza, three times daily).

Adherence and Compliance

Barriers to Adherence

Adherence is the single greatest challenge in medical glaucoma management. Barriers include complex regimens with multiple bottles and dosing times, medication cost and insurance coverage issues, side effects such as redness and stinging, the asymptomatic nature of glaucoma (patients cannot feel the benefit of treatment), difficulty with drop instillation (particularly in elderly patients with arthritis or hand tremor), and simple forgetfulness.

Strategies to Improve Adherence

Multiple strategies can address poor adherence. Simplifying the regimen by using fixed combinations and once-daily agents reduces the burden. Patient education emphasizing the irreversible nature of glaucomatous vision loss can improve motivation. Dosing aids such as alarms, smartphone apps, and electronic monitors provide reminders. Drop delivery aids like the Autodrop and Nanodropper devices reduce difficulty and waste. Preservative-free formulations help patients with ocular surface disease who otherwise stop medications due to discomfort. Considering selective laser trabeculoplasty (SLT) as first-line therapy, supported by the LiGHT trial, can eliminate the drop burden entirely. Sustained-release drug delivery platforms, including the bimatoprost intracameral implant (Durysta) and the travoprost intracameral device (iDose TR), represent emerging solutions that bypass adherence issues altogether.

<image>Pharmacology summary diagram showing the sites of action of all glaucoma drug classes on a cross-sectional anterior segment illustration. The ciliary body is labeled with arrows showing aqueous production and the agents that reduce it: beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. The trabecular meshwork is labeled with agents that increase conventional outflow: miotics (pulling on scleral spur), rho-kinase inhibitors (relaxing TM). The uveoscleral pathway through the ciliary muscle is labeled with prostaglandin analogs and alpha-agonists increasing non-conventional outflow. The episcleral veins are labeled with rho-kinase inhibitors reducing episcleral venous pressure. Each drug class is color-coded with its mechanism and approximate IOP reduction percentage.</image>

<image>Clinical photograph montage showing ocular side effects of glaucoma medications. Five panels: (1) Prostaglandin-associated periorbitopathy (PAPA) — deepened upper lid sulcus, periorbital fat atrophy, and iris heterochromia in a unilaterally treated patient; (2) Conjunctival hyperemia from prostaglandin analog use; (3) Allergic follicular conjunctivitis from brimonidine showing inferior fornix follicles and lid edema; (4) Cornea verticillata from netarsudil showing whorl-like golden-brown deposits in the corneal epithelium (similar to Fabry disease pattern); (5) Miotic pupil from pilocarpine compared to the untreated dilated fellow eye. Label each medication and side effect.</image>

Key Clinical Pearls

Prostaglandin analogs are the first-line therapy for POAG because they offer the best efficacy (25 to 35% IOP reduction), require only once-daily dosing, and have minimal systemic side effects. The clinician must always ask about asthma and COPD before prescribing topical beta-blockers, as even eye drops can cause fatal bronchospasm through systemic absorption. All patients using topical glaucoma medications should be taught nasolacrimal occlusion -- pressing on the inner corner of the eye for two to five minutes after instillation -- to minimize systemic absorption by 50 to 70%. Brimonidine is contraindicated in infants and toddlers under two years of age due to the risk of life-threatening CNS depression. Topical CAIs should be avoided in Fuchs dystrophy or other conditions with low endothelial cell counts, as they can accelerate irreversible corneal decompensation. Rocklatan (netarsudil/latanoprost) is the most potent single-bottle IOP-lowering agent currently available, providing 30 to 36% IOP reduction. Adherence is the Achilles heel of medical glaucoma therapy, and clinicians should simplify regimens and consider SLT or sustained-release drug delivery platforms for non-adherent patients. The LiGHT trial demonstrated that SLT as first-line treatment was at least as effective as topical medications and more cost-effective at three years.

References

• Weinreb RN, et al. Oral and topical carbonic anhydrase inhibitors. In: The Glaucomas. Mosby, 1996.
• Gazzard G, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505-1516.
• Krupin T, et al. Low-Pressure Glaucoma Treatment Study. Ophthalmology. 2011;118(12):2525-2532.
• Serle JB, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2018;186:116-127.
• AAO BCSC Section 10: Glaucoma. 2023-2024.

Read this lecture as Markdown